Skip to Content

Fibertab (polycarbophil) Disease Interactions

There are 5 disease interactions with Fibertab (polycarbophil):

Major

Bulk producing laxatives (applies to Fibertab) intestinal obstruction

Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction. Bulk producing laxatives can exacerbate these conditions.

References

  1. "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.
  2. "Product Information. FiberCon (polycarbophil)." Lederle Laboratories, Philadelphia, PA.
  3. "Product Information. Unifiber (cellulose)." Nich Pharmaceuticals Inc, Roanoke, TX.
Major

Laxatives (applies to Fibertab) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  2. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
Major

Laxatives (applies to Fibertab) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratorries Inc, Fort Worth, TX.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet, Lynchburg, VA.
  5. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc, Woodbridge, NJ.
View all 5 references
Moderate

Bulk producing laxatives (applies to Fibertab) renal dysfunction

Moderate Potential Hazard, High plausibility.

Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose. Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.

References

  1. "Product Information. FiberCon (polycarbophil)." Lederle Laboratories, Philadelphia, PA.
  2. "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceutic, Cincinnati, OH.
Moderate

Polycarbophil (applies to Fibertab) hypercalcemia

Moderate Potential Hazard, High plausibility.

The use of polycarbophil may cause hypercalcemia. Polycarbophil is supplied as the calcium salt and contains approximately 150 mg (7.6 mEq) of calcium per tablet. Polycarbophil calcium releases calcium ions in the GI tract.

References

  1. "Product Information. FiberCon (polycarbophil)." Lederle Laboratories, Philadelphia, PA.

Fibertab (polycarbophil) drug interactions

There are 28 drug interactions with Fibertab (polycarbophil)

Fibertab (polycarbophil) alcohol/food interactions

There is 1 alcohol/food interaction with Fibertab (polycarbophil)

More about Fibertab (polycarbophil)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.